Skip to main content
All lobbying filings

CORMEDIX INC.

Lobbying for CORMEDIX INC. · Biopharmaceutical company.

 Amended
The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Oct 20, 2026.
 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$110,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
New Jersey

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Health Issues

H.R. 6214/S. 2730, Kidney Care Access Protection Act, including provisions related to healthcare and Medicare H.R. 7352/S. 4815, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2026

 Bills named in this filing 4

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem